Tirzepatide

Type 2 Diabetes

Tirzepatide is used to help control blood sugar levels in adults with type 2 diabetes mellitus. It is intended to be used in combination with a healthy diet and regular physical activity.

Chronic Weight Management

This medication is also used for long-term weight management in adults who meet specific criteria:

• Individuals with obesity, defined as a body mass index (BMI) of 30 or greater.
• Individuals who are overweight, defined as a BMI of 27 or greater, and who also have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol.

It is used alongside a reduced-calorie diet and increased physical activity to help patients lose weight and maintain weight loss.

Important Limitations

Tirzepatide is not used to treat type 1 diabetes. It has not been studied in people who have had inflammation of the pancreas (pancreatitis).

Dual Hormone Action

Tirzepatide is a medication known as a dual agonist. It works by activating receptors for two different incretin hormones produced naturally in the gut:

• Glucagon-like peptide-1 (GLP-1): This hormone helps the pancreas release insulin when blood sugar is high and prevents the liver from making too much sugar.
• Glucose-dependent insulinotropic polypeptide (GIP): This hormone also stimulates insulin production and is thought to improve how the body processes sugar and fat.

Blood Sugar Control

By mimicking these hormones, tirzepatide helps the body manage glucose more effectively. It increases insulin secretion after meals and decreases the amount of glucagon, a hormone that raises blood sugar, circulating in the blood.

Digestion and Appetite

Tirzepatide also affects how the body processes food and perceives hunger in the following ways:

• It slows down the rate at which the stomach empties, which helps prevent sharp spikes in blood sugar after eating.
• It acts on areas of the brain that control appetite, helping people feel full longer and reducing overall food intake.

Common Side Effects

Many people experience digestive issues when taking tirzepatide, especially when first starting the medication or increasing the dose. These symptoms often improve over time and may include:

• Nausea and vomiting
• Diarrhea or constipation
• Stomach pain or discomfort
• Indigestion or heartburn
• Decreased appetite
• Injection site reactions, such as redness, itching, or pain

Serious Side Effects

Some side effects can be severe and require prompt medical evaluation. Seek medical help if you experience any of the following:

• Pancreatitis: Severe, persistent pain in the upper stomach area that may radiate to the back.
• Gallbladder problems: Pain in the upper right abdomen, fever, or yellowing of the skin or eyes.
• Kidney problems: Signs of dehydration or changes in urination, which can occur if severe vomiting or diarrhea leads to fluid loss.
• Severe allergic reactions: Swelling of the face, tongue, or throat, difficulty breathing, or a severe skin rash.
• Vision changes: New or worsening eye problems, particularly in patients with a history of diabetic retinopathy.
• Low blood sugar (hypoglycemia): Dizziness, shakiness, or confusion, especially when used alongside other diabetes medications.

Boxed Warning: Thyroid C-cell Tumors

In animal studies, tirzepatide caused thyroid C-cell tumors. It is unknown whether it causes these tumors, including medullary thyroid carcinoma (MTC), in humans. This medication is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Pancreatitis

Acute pancreatitis has been reported in patients treated with tirzepatide. Signs of pancreatitis include severe abdominal pain that may radiate to the back, with or without vomiting. If pancreatitis is suspected, the medication is typically discontinued.

Severe Gastrointestinal Disease

Tirzepatide is associated with gastrointestinal adverse reactions, which can sometimes be severe. Because the medication slows gastric emptying, it has not been studied in and is not recommended for patients with severe gastrointestinal disease, including severe gastroparesis.

Kidney and Gallbladder Issues

• Kidney Injury: Severe gastrointestinal side effects, such as nausea and diarrhea, can lead to dehydration. This fluid loss may cause acute kidney injury.
• Gallbladder Disease: Acute gallbladder events, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis), have occurred in clinical trials.

Hypoglycemia

The risk of low blood sugar (hypoglycemia) is increased when tirzepatide is used in combination with insulin or insulin secretagogues, such as sulfonylureas. Adjustments to the doses of these concurrent medications may be necessary to reduce the risk.

Diabetic Retinopathy

Rapid improvement in glucose control has been linked to the temporary worsening of diabetic retinopathy. Patients with a history of this condition are typically monitored for changes in vision during treatment.

Hypersensitivity Reactions

Serious hypersensitivity reactions, such as anaphylaxis or angioedema, have been reported. Tirzepatide is contraindicated in patients with a known serious hypersensitivity to the drug or any of its components.

Pregnancy and Contraception

Tirzepatide may cause fetal harm and is not recommended during pregnancy. Additionally, the medication may reduce the effectiveness of oral contraceptives by delaying stomach emptying. Switching to a non-oral contraceptive or adding a barrier method for four weeks after starting the drug and after each dose increase is often advised.

Pregnancy

There is limited data on the use of tirzepatide in pregnant women. In animal studies, the medication was associated with lower fetal weight and structural abnormalities. Because of these potential risks, healthcare providers typically advise stopping tirzepatide if you become pregnant or are planning to become pregnant.

If you are planning a pregnancy, it is often recommended to stop using tirzepatide at least 2 months before trying to conceive to ensure the drug is cleared from your system.

Birth Control

Tirzepatide slows the emptying of the stomach, which can interfere with how the body absorbs oral birth control pills. This may make oral contraceptives less effective. If you use birth control pills, your healthcare provider may suggest:

• Switching to a non-oral contraceptive method (such as a patch, ring, or injection).
• Adding a barrier method (such as condoms) for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase.

Breastfeeding

It is currently unknown whether tirzepatide passes into human breast milk or if it affects milk production. Because many drugs are excreted in human milk, caution is advised. You should discuss the potential risks and benefits with your healthcare provider to decide if you should continue the medication while breastfeeding.

Dosage Forms

Tirzepatide is administered as an injection under the skin (subcutaneously). It is supplied as a clear, colorless to slightly yellow liquid solution in the following formats:

• Single-dose pre-filled pens: These are disposable injection devices intended for a single use.
• Single-dose vials: These contain the medication in a liquid form for administration using a separate syringe.

The medication is intended for injection into the skin of the abdomen, thigh, or upper arm.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) has approved tirzepatide for several specific medical uses:

• Type 2 Diabetes: Approved as an adjunct to diet and exercise to improve glycemic control in adults.
• Chronic Weight Management: Approved for adults with obesity, or those who are overweight and have at least one weight-related condition (such as high blood pressure or high cholesterol).
• Obstructive Sleep Apnea: Approved for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight.

Boxed Warning

Tirzepatide carries a boxed warning because it has been shown to cause thyroid C-cell tumors in animal studies. It is currently unknown whether the medication causes these tumors in humans. Because of this risk, tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Regulatory Safety Communications

The FDA has issued warnings regarding the use of unapproved or compounded versions of GLP-1 receptor agonists, which include tirzepatide. The agency has expressed concern that compounded versions may not meet the same safety, quality, and effectiveness standards as the FDA-approved products. Patients are advised to obtain this medication only through licensed healthcare providers and pharmacies.

How Tirzepatide Works for Weight Loss

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It works by activating receptors for two naturally occurring hormones in the body. These hormones help regulate blood sugar levels and signal the brain that the body is full, which can lead to decreased food intake and weight loss.

Eligibility and Use

The medication is intended for long-term weight management in adults who meet specific criteria:

• A body mass index (BMI) of 30 kg/m² or greater (obesity).
• A BMI of 27 kg/m² or greater (overweight) in the presence of at least one weight-related medical condition, such as high blood pressure, type 2 diabetes, or high cholesterol.

Tirzepatide is meant to be used alongside a reduced-calorie diet and increased physical activity. It is administered once weekly as a subcutaneous injection in the abdomen, thigh, or upper arm.

Effectiveness

Clinical trials have demonstrated that tirzepatide can lead to significant reductions in body weight compared to a placebo. In some studies comparing tirzepatide to other weight-loss medications like semaglutide, tirzepatide was associated with greater average weight loss, though individual results vary.

Important Considerations

While effective for weight loss, tirzepatide is not a substitute for healthy lifestyle changes. It is not recommended for use with other tirzepatide-containing products or other GLP-1 receptor agonists. Patients should discuss their medical history with a healthcare provider, especially if they have a history of pancreatitis, kidney problems, or severe stomach issues.